Drospirenone, a New Progestogen, for Postmenopausal Women with Hypertension

@article{Mallareddy2007DrospirenoneAN,
  title={Drospirenone, a New Progestogen, for Postmenopausal Women with Hypertension},
  author={M. Mallareddy and V. Hanes and W. White},
  journal={Drugs \& Aging},
  year={2007},
  volume={24},
  pages={453-466}
}
The prevalence of hypertension increases in women after the menopause. Associated with the rise in postmenopausal blood pressure (BP) are increased salt sensitivity and imbalance between the renin-angiotensin-aldosterone system and nitric oxide pathways that lead to sodium and water retention. Drospirenone is the first synthetic progestogen with antialdosterone activity similar to natural progesterone. Drospirenone counteracts the salt- and water-retaining effects of estrogen and causes… Expand
Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review
TLDR
All studies agree that the combination of estradiol 1 mg plus drospirenone 2 mg is a good choice for postmenopausal women with vasomotor symptoms. Expand
The “newer” progestogens and postmenopausal hormone therapy (HRT)
  • A. Schindler
  • Biology, Medicine
  • The Journal of Steroid Biochemistry and Molecular Biology
  • 2014
TLDR
Three "newer progestogens" are scrutinized regarding their various actions, in combination with estradiol; the progestogenic include dienogest, drospirenone and nomegestrol acetate. Expand
Novel therapeutic targets for hypertension
TLDR
Modulation of the renin–angiotensin–aldosterone system (RAAS) provides the rationale for current antihypertensive therapies, including the relatively new agents eplerenone and aliskiren, and new minimally invasive surgical procedures have revived the concept of renal denervation. Expand
Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients: a pilot study.
TLDR
The OC containing drospirenone does not seem to affect the surrogate markers of cardiovascular risk in lean patients with PCOS. Expand
New hormonal therapies and regimens in the postmenopause: routes of administration and timing of initiation
  • R. Sitruk-Ware
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2007
TLDR
The combination of non-oral administration of estradiol and local delivery of progesterone or a progestin such as levonorgestrel by means of gels, sprays, vaginal rings or intrauterine systems would represent new methods of replacement therapy for the menopausal woman, improving compliance and minimizing the risks of hormone replacement. Expand
Cardiovascular Risk During the Menopause
TLDR
Although initial experimental data and results of observational studies suggest that hormone replacement (HRT) is associated with a reduction in the risk of heart disease, the results for events such as stroke or thromboem- bolism are less clear, HRT therapy should not be initiated to prevent vascular disease among postmenopausal women. Expand
Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics
TLDR
It is demonstrated that the molecular pharmacology of current MR antagonists is on the one hand far from well understood and, on the other hand, still offers room for improvements. Expand
Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies.
  • A. Boldo, W. White
  • Medicine
  • Endocrinology and metabolism clinics of North America
  • 2011
TLDR
The effects of different classes of oral contraceptive agents and hormonal replacement therapy on BP and associated effects on other cardiovascular risk factors are covered in this article. Expand
A new generation of progesterone receptor modulators
TLDR
This review will focus primarily on the newer generation of PR modulators derived from structurally unique chemical scaffolds, and presents numerous examples of unique non-steroidal PR antagonists in various stages of characterization and development. Expand
Mineralocorticoid receptor haplotype moderates the effects of oral contraceptives and menstrual cycle on emotional information processing
TLDR
In MR-haplotype 1/3 carriers, ML women gambled more than EF women when their risk to lose was relatively small and showed more risky decision-making, which may support previous observations in female carriers of MR- haplotype 2 in a naturalistic cohort study. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 59 REFERENCES
Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women.
TLDR
In hypertensive postmenopausal women, treatment with DRSP/E2 was not associated with a greater incidence of hyperkalemia than with placebo in patients with and without type 2 diabetes mellitus and concomitant use of ACE inhibitors, angiotensin receptor antagonists, or ibuprofen. Expand
Effects of a New Hormone Therapy, Drospirenone and 17-&bgr;-Estradiol, in Postmenopausal Women With Hypertension
TLDR
Data show that DRSP combined with E2 significantly reduces BP in postmenopausal women with hypertension and did not induce significant increases in serum potassium, which may lead to a new benefit for this novel hormone therapy in postwomen's hypertension. Expand
Conception and pharmacodynamic profile of drospirenone
TLDR
DRSP prevented the mild increase of blood pressure seen under a conventional levonorgestrel-containing contraceptive and even tended to reduce pretreatment blood pressure, and powerful antiandrogenic effects were seen in gonad intact and testosterone substituted castrated male rats. Expand
Antihypertensive Effects of Drospirenone With 17&bgr;-Estradiol, a Novel Hormone Treatment in Postmenopausal Women With Stage 1 Hypertension
TLDR
Combination therapy with DRSP/E2 significantly lowered both clinic and 24-hour systolic BP in postmenopausal women with stage 1 systolics hypertension, which may lead to benefit for cardiovascular risk reduction in this population of women. Expand
Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril.
TLDR
A significant additive BP-lowering effect of DRSP/E2 on both systolic and diastolic BP in hypertensive postmenopausal women receiving ENA is suggested, consistent with an antimineralocorticoid effect. Expand
Medroxyprogesterone Acetate But Not Drospirenone Ablates the Protective Function of 17β-Estradiol in Aldosterone Salt-Treated Rats
TLDR
The hypothesis of complex interactions among estrogen, progesterone, glucocorticoid, androgen, and mineralocortICoid receptor signaling in cardiovascular injury and inflammation is supported. Expand
Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide
TLDR
DRSP/E2 substantially lowers systolic and diastolic blood pressure when added to existing antihypertensive therapy with HCTZ in hypertensive postmenopausal women and has a potassium-sparing effect that counteracts HCTz-induced potassium loss. Expand
Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure
TLDR
A new progestogen (Drospirenone) with an antimineralocorticoid effect like that of progesterone is described that slightly lowers body weight and blood pressure in a contraceptive formulation together with EE. Expand
Drospirenone: pharmacology and pharmacokinetics of a unique progestogen.
TLDR
Based on the biochemical and pharmacodynamic data, drospirenone appears to be a viable alternative to the currently available progestogens. Expand
Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
TLDR
To the authors' knowledge, this is the first report on a combined OC that leads to a small decrease in body weight and blood pressure and may be especially beneficial for women susceptible for a gain in weight and a rise in blood pressure. Expand
...
1
2
3
4
5
...